) -- Back by popular demand,
FDA Drug Approval Contest for 2013 -- with a few twists.
Your challenge: Correctly guess the outcome of the 12 regulatory events listed below. As a kicker to the contest, you're required to predict the outcome of a closely followed European drug approval decision, three FDA advisory panels and an accelerated approval meeting between a certain drug company and FDA officials.
Don't forget to answer the bonus question, as well.
To participate in the drug approval contest, please post your predictions to each of the 13 questions in the
under this story.
Post your picks by Friday, March 8 at 4 pm ET.
Entries posted after the deadline will not count, so don't be tardy with your picks. Enter now!
As with my previous drug-approval contests, winners will be lauded for their intelligence on Twitter and in future columns. Losers will be mocked gently.
: The FDA will grant the company's request to seek accelerated approval for eteplirsen. Yes or No?
: The European Medicine Agency's CHMP will recommend approval of the weight-loss drug Belviq. Yes or No?
: FDA advisory panel for Probuphine on March 21. Positive or negative vote?
: FDA approval decision for APF530 on March 27: Approve or Reject?
: FDA approval decision for BG-12 on March 28. Approve or Reject?
: FDA approval decision for oral Remodulin on March 29. Approve or Reject?
: FDA approval decision for Amitiza on April 26. Approve or Reject?
: FDA approval decision for Lymphoseek on April 30. Approve or Reject?
: FDA approval decision for Procysbi on April 30. Approve or Reject?
: FDA advisory panel for Tivopath on May 2. Positive or negative vote?
: FDA advisory panel for ChemoSat (now known as Melblez) on May 2. Positive or negative vote?
: FDA approval decision for Melblez on June 14. Approve or Reject?
13. Bonus question: Will the
phase III study of palifosfamide in sarcoma be successful (defined as meeting the PFS primary endpoint with statistical significance.) Yes or No?
-- Reported by Adam Feuerstein in Boston.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.